HUP0104439A2 - Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof - Google Patents

Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof

Info

Publication number
HUP0104439A2
HUP0104439A2 HU0104439A HUP0104439A HUP0104439A2 HU P0104439 A2 HUP0104439 A2 HU P0104439A2 HU 0104439 A HU0104439 A HU 0104439A HU P0104439 A HUP0104439 A HU P0104439A HU P0104439 A2 HUP0104439 A2 HU P0104439A2
Authority
HU
Hungary
Prior art keywords
agent
administered
corticosteroid
solution
antagonist
Prior art date
Application number
HU0104439A
Other languages
Hungarian (hu)
Inventor
Subhashis Banerjee
Adam Carter
Tariq Ghayur
Les Sekut
Daniel E. Tracey
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of HUP0104439A2 publication Critical patent/HUP0104439A2/en
Publication of HUP0104439A3 publication Critical patent/HUP0104439A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A tal lm ny értelmében egy kortikoszteroidot egy olyan szerrel kombinlva adnak be egy betegnek, amely szer antagoniz l egy, az IFN-gképződését szab lyozó targetet, és így az "nmag ban beadottkortikoszteroidhoz képest modul lj k a betegnek a kortikoszteroidraadott v lasz t. A tal lm ny szerinti megold sok egyikében egy IL-18antagonista szert adnak be. Egy m sik megold s értelmében egyinterleukin-12 (IL-12) antagonista szert adnak be. Egy tov bbi megolds szerint egy NK-sejt antagonista szert adnak be. Az egyik előny"smegold s értelmében a szer egy kaszp z-csal dba tartozó prote znak egyinhibitora, előny"sen egy ICE inhibitor. Egy m sik előny"s megold sszerint a szer egy anti-IL-12 monoklon lis antitest. Egy m sik előny"smegold s szerint a szer egy anti-asialo-GM1 antitest vagy egy NK1.1antitest. Tov bbi előny"s szerek péld ul a foszfodiészter z IVinhibitorok és a béta-2 agonist k. A tal lm ny t rgy hoz tartozógyógyszerkészítményeket kül"nféle gyullad sos és immunológiaibetegségek és rendellenességek kezelésére lehet felhaszn lni. A tal lmny kiterjed olyan gyógyszerkészítményekre is, amelyek egy IFN-gképződést szab lyozó targetet antagoniz ló szert, kortikoszteroidot ésgyógyszerészetileg elfogadható hordozót tartalmaznak. Az egyik előny"stal lm ny szerinti gyógyszerkészítmény egy ICE inhibitort, egykortikoszteroidot és egy gyógyszerészetileg elfogadható hordozóttartalmaz. ÓAccording to the findings, a corticosteroid is administered to a patient in combination with an agent that antagonizes a target that regulates the production of IFN-g, thus modulating the patient's response to corticosteroids compared to the corticosteroid administered alone. In one of the solutions according to the present invention, an IL-18 antagonist is administered. In another solution, an interleukin-12 (IL-12) antagonist is administered. In a further solution, an NK cell antagonist is administered. One of the advantages According to "smegold", the agent is an inhibitor of a caspase-related protein, preferably an ICE inhibitor. According to another advantageous solution, the agent is an anti-IL-12 monoclonal antibody. According to another preferred solution, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents are, for example, phosphodiester IV inhibitors and beta-2 agonists. The pharmaceutical preparations belonging to the present substance can be used for the treatment of various inflammatory and immunological diseases and disorders. The present invention also covers pharmaceutical preparations that contain a target antagonizing agent that regulates IFN-g formation, a corticosteroid and a pharmaceutically acceptable carrier. One Advantageously, the pharmaceutical composition according to the invention contains an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier. HE

HU0104439A 1997-03-18 1998-03-12 Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof HUP0104439A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US1634698A 1998-01-30 1998-01-30
PCT/US1998/004916 WO1998041232A2 (en) 1997-03-18 1998-03-12 Compositions for modulating responsiveness to corticosteroids

Publications (2)

Publication Number Publication Date
HUP0104439A2 true HUP0104439A2 (en) 2002-04-29
HUP0104439A3 HUP0104439A3 (en) 2002-08-28

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104439A HUP0104439A3 (en) 1997-03-18 1998-03-12 Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof

Country Status (20)

Country Link
EP (1) EP0998300A1 (en)
JP (1) JP2002504091A (en)
KR (1) KR20000076420A (en)
CN (1) CN1269722A (en)
AU (1) AU734756B2 (en)
BG (1) BG103808A (en)
BR (1) BR9810409A (en)
CA (1) CA2282845A1 (en)
DE (1) DE998300T1 (en)
ES (1) ES2146192T1 (en)
HU (1) HUP0104439A3 (en)
ID (1) ID22975A (en)
IL (1) IL131815A0 (en)
NO (1) NO994506L (en)
NZ (1) NZ337769A (en)
PL (1) PL336464A1 (en)
SI (1) SI20110A (en)
SK (1) SK122199A3 (en)
TR (1) TR199902615T2 (en)
WO (1) WO1998041232A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (en) * 1997-10-17 2001-05-30 Smithkline Beecham Corp USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
CA2276420A1 (en) * 1997-10-31 1999-05-14 Terry Strom Use of anti-il-12 antibodies in transplantation rejection
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
ATE295177T1 (en) * 1998-03-16 2005-05-15 Cytovia Inc DIPEPTIDE KASPASE INHIBITORS AND THEIR USE
EP1140206A4 (en) * 1998-11-27 2002-04-10 Technion Res & Dev Foundation Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
EP1336654A1 (en) * 1998-12-09 2003-08-20 Protein Design Labs, Inc. Method of treating psoriasis using anti-gamma interferon antibody
EP1165490B1 (en) 1999-03-16 2006-08-16 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE19915465A1 (en) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes
ATE363465T1 (en) 1999-04-09 2007-06-15 Cytovia Inc CASPASE INHIBITORS AND THEIR USE
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
EA200200301A1 (en) 1999-08-27 2002-08-29 Сайтовиэ, Инк. SUBSTITUTED COLLECTION CENTER
WO2001019373A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AU2001236807A1 (en) 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
WO2001093909A2 (en) * 2000-06-06 2001-12-13 Glaxo Group Limited Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
AU7250301A (en) * 2000-06-22 2002-01-02 Willy Ben Moussa Ben Mohammed Use of glucocorticosteroids for producing a medicament to treat oligotrichia
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EE05534B1 (en) * 2001-01-29 2012-04-16 Applied Research Systems Ars Holding N.V. Use of IL-18 inhibitors in the manufacture of a medicament for the treatment and / or prevention of cardiomyopathy
DK1425028T3 (en) * 2001-05-16 2010-03-01 Yeda Res & Dev Use of IL-18 inhibitors to treat or prevent sepsis
ATE464068T1 (en) 2001-06-26 2010-04-15 Amgen Fremont Inc ANTIBODIES AGAINST OPGL
WO2003030823A2 (en) * 2001-10-05 2003-04-17 Combinatorx, Incorporated Combinations for the treatment of immunoinflammatory disorders
JP2003342196A (en) * 2002-05-31 2003-12-03 Mukku:Kk Composition for intravenous injection, method of production for the same and its preparation
AR041386A1 (en) * 2002-09-24 2005-05-18 Combinatorx Inc METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMATORY CYTOKINS
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
EP1752159A4 (en) * 2004-05-17 2009-07-01 Univ Keio Medicinal composition and therapeutic method
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DK1808446T3 (en) * 2004-07-16 2012-05-14 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
CA2584169A1 (en) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for chronic skin disease
ES2384641T3 (en) 2005-07-14 2012-07-10 Lithera, Inc. Lipolytic formulation that enhances the release maintained for the localized treatment of adipose tissue
JP2010506941A (en) * 2006-10-17 2010-03-04 リセラ，インク． Methods, compositions and formulations for the treatment of thyroid ophthalmopathy
CN104524567A (en) 2007-01-16 2015-04-22 阿布维公司 Methods for treating psoriasis
WO2008121301A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human il-12 antibodies
KR20100126515A (en) 2008-03-18 2010-12-01 아보트 러보러터리즈 Methods for treating psoriasis
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
EA201270784A1 (en) 2010-11-24 2013-04-30 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" MONOTHERAPE TREATMENT COMPOSITIONS OF SELECTIVE LIPOPHIL AND BETA-AGONIST OF LONG ACTION AND METHODS OF COSMETIC TREATMENT FOR OBESITY AND COUNTER-ROOTING
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
AU2022353032A1 (en) * 2021-09-22 2024-03-28 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
GB2235626B (en) * 1989-09-08 1994-02-09 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (en) * 1992-07-31 1994-03-31 Glaxo Group Ltd PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
JP3573213B2 (en) * 1995-04-14 2004-10-06 グラクソ、ウェルカム、インコーポレーテッド Metered dose inhaler for beclomethasone dipropionate

Also Published As

Publication number Publication date
CA2282845A1 (en) 1998-09-24
KR20000076420A (en) 2000-12-26
BR9810409A (en) 2000-08-22
PL336464A1 (en) 2000-06-19
NO994506D0 (en) 1999-09-17
EP0998300A1 (en) 2000-05-10
BG103808A (en) 2000-07-31
CN1269722A (en) 2000-10-11
TR199902615T2 (en) 2000-03-21
AU734756B2 (en) 2001-06-21
NO994506L (en) 1999-11-17
AU6760498A (en) 1998-10-12
NZ337769A (en) 2002-09-27
WO1998041232A2 (en) 1998-09-24
ES2146192T1 (en) 2000-08-01
IL131815A0 (en) 2001-03-19
HUP0104439A3 (en) 2002-08-28
ID22975A (en) 1999-12-23
WO1998041232A3 (en) 2000-10-05
SK122199A3 (en) 2000-12-11
DE998300T1 (en) 2001-03-01
SI20110A (en) 2000-06-30
JP2002504091A (en) 2002-02-05

Similar Documents

Publication Publication Date Title
HUP0104439A2 (en) Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof
EA199900454A1 (en) STABLE POWDER PREPARATIONS, WHICH ARE IN GLASS-SHAPED CONDITION
WO2001019373A3 (en) Methods and compositions for modulating responsiveness to corticosteroids
ATE113846T1 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF MYOCARDIAL INFARCTS.
MY131434A (en) Angiotensin ii antagonists
ES2079994B1 (en) PHARMACEUTICAL FORMULATION BASED ON POLYMIXINE-TRIMETOPRIM AND AN ANTI-INFLAMMATORY AGENT FOR ITS TOPICAL OPHTHALMIC AND ETHICAL USE.
CA2274825A1 (en) Substituted nitrogen containing heterocycles as inhibitors of p38 protein kinase
NZ500589A (en) Leptin (ob protein) and active fractions and fragments thereof as inhibitors of tumor cell proliferation
ES8200080A1 (en) Long lasting agonists and antagonists of LHRH and compositions containing them.
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
EE05213B1 (en) Use of a L mphotoxin β receptor (LT-β-R) blocking agent and a pharmaceutical composition comprising a LT-β-R blocking agent and a CD40L blocking agent
DE69927582D1 (en) NEW ANALOG OF 16-HYDROXYEICOSATETRAIC ACID
ATE163196T1 (en) HUMAN IL-4 MUTANT PROTEINS
ITMI922331A1 (en) USE OF PARATORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES, FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS USEFUL IN THE PREVENTION AND THERAPY OF ABORTION AND PRE-TERM BIRTH AND IN GENERAL FOR THE TREATMENT OF THE MANAGEMENT
ES2131528T3 (en) NEW POLYPEPTIDES AND THEIR USE.
SE9402880D0 (en) New peptide derivatives
DK0641216T3 (en) Pharmaceutical preparation containing IL-6
IT1256623B (en) TACHYCHININ ANTAGONISTS, PROCEDURE FOR THEIR PREPARATION AND USE IN PHARMACEUTICAL FORMULATIONS
DK0917460T3 (en) Cyclosporin formulation
SE9403389D0 (en) Pharmaceutical composition containing derivatives of sex hormones
DK0713386T3 (en) Spray formulation with cooling effect
IL122659A (en) Pharmaceutical compositions for the treatment of dyspeptic symptoms comprising angiotensin ii type receptor antagonists
Konttinen et al. Mast cell derangement in salivary glands in patients with Sjögren's syndrome
NO20006022L (en) Recombinant human interferon <beta> -1A (IFN- <beta> -1A) formulation
McIntush et al. Concentration of tissue inhibitor of metalloproteinases (TIMP)-1 in ovine follicular fluid and serum